{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abatacept+%28BMS-188667%29", "query": { "intervention": "Abatacept (BMS-188667)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 203, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abatacept+%28BMS-188667%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T21:56:23.496Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05335928", "title": "Abatacept in Immune Checkpoint Inhibitor Myocarditis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myocarditis Acute", "Cancer" ], "interventions": [ { "name": "Abatacept plus", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2022-07-02", "completion_date": "2029-10-09", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 29, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05335928" }, { "nct_id": "NCT00929864", "title": "Abatacept Versus Adalimumab Head-to-Head", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 869, "start_date": "2009-10", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-02-04", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00929864" }, { "nct_id": "NCT00287547", "title": "Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis Vulgaris" ], "interventions": [ { "name": "CTLA4Ig / Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 144, "start_date": "1997-03", "completion_date": "1998-01", "has_results": false, "last_update_posted_date": "2011-04-25", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 10, "location_summary": "San Diego, California • Chicago, Illinois • Boston, Massachusetts + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287547" }, { "nct_id": "NCT00035529", "title": "A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "BMS 188667 (Abatacept)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": null, "start_date": "2001-11", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2010-12-06", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 10, "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Worcester, Massachusetts + 7 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Newark", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035529" }, { "nct_id": "NCT05345717", "title": "Novel Desensitization Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplantation", "End Stage Kidney Disease (ESRD)" ], "interventions": [ { "name": "Belatacept Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 5, "start_date": "2022-05-01", "completion_date": "2025-09-12", "has_results": false, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05345717" }, { "nct_id": "NCT05669001", "title": "A Study of TCD601 in de Novo Renal Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Transplantation" ], "interventions": [ { "name": "TCD601", "type": "BIOLOGICAL" }, { "name": "belatacept", "type": "BIOLOGICAL" }, { "name": "ATG", "type": "DRUG" }, { "name": "TAC", "type": "DRUG" }, { "name": "MPA", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ITB-Med LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 76, "start_date": "2023-12-28", "completion_date": "2026-04-10", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 18, "location_summary": "Sacramento, California • San Francisco, California • Tampa, Florida + 15 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05669001" }, { "nct_id": "NCT00119678", "title": "Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2005-09", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2014-09-22", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 12, "location_summary": "Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00119678" }, { "nct_id": "NCT00306878", "title": "Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psoriasis Vulgaris" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 45, "start_date": "1995-08", "completion_date": "1997-05", "has_results": false, "last_update_posted_date": "2011-04-13", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00306878" }, { "nct_id": "NCT01350804", "title": "Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "AIN457", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 551, "start_date": "2011-09", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-05-23", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 44, "location_summary": "Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Vestavia Hills", "state": "Alabama" }, { "city": "Freemont", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01350804" }, { "nct_id": "NCT00719225", "title": "A Belatacept Compassionate Use Study for Patients With a Kidney Transplant", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Renal Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2021-11-23", "last_synced_at": "2026-09-29T21:56:23.496Z", "location_count": 7, "location_summary": "La Jolla, California • Atlanta, Georgia • New Iberia, Louisiana + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Iberia", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719225" } ] }